Login / Signup

Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.

Barbara Deschler-BaierBhavana KondaErminia MassarelliMimi I HuLori J WirthXiaojian XuJennifer WrightRoderick J Clifton-Bligh
Published in: The Journal of clinical endocrinology and metabolism (2024)
These data support selpercatinib as an effective therapy against RET-mutant pheochromocytoma, adding to the diversity of RET-activated tumor types that may benefit from targeted RET inhibition.
Keyphrases
  • wild type
  • electronic health record
  • big data
  • mesenchymal stem cells
  • drug delivery
  • cell therapy